CoChat
Sign Up
Cited by 264Silymarin and Mushroom PoisoningLiver Disease Diagnosis and TreatmentNigella sativa pharmacological applications

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis

Wah Kheong, Chan, Nik Mustapha, Nik Raihan, Mahadeva, Sanjiv·2017·Clinical Gastroenterology and Hepatology
DOI 10.1016/j.cgh.2017.04.016
Open this paper in CoChat — free account

Abstract

Background & aims Silymarin is a complex mixture of 6 major flavonolignans and other minor polyphenolic compounds derived from the milk thistle plant Silybum marianum; it has shown antioxidant, anti-inflammatory and antifibrotic effects, and may be useful in patients with nonalcoholic fatty liver disease (NAFLD). We aimed to study the efficacy of silymarin in patients with nonalcoholic steatohepatitis (NASH)-the more severe form of NAFLD.Methods We performed a randomized, double-blind, placebo-controlled trial of consecutive adults with biopsy-proven NASH and a NAFLD activity score (NAS) of 4 or more at a tertiary care hospital in Kuala Lumpur, Malaysia, from November 2012 through August 2014. Patients were randomly assigned to groups given silymarin (700 mg; n = 49 patients) or placebo (n = 50 patients) 3 times daily for 48 weeks. After this 48-week period, liver biopsies were repeated. The primary efficacy outcome was a decrease of 30% or more in NAS; findings from 48-week liver biopsies were compared with those from the baseline biopsy. Secondary outcomes included changes in steatosis, lobular inflammation, hepatocyte ballooning, NAS and fibrosis score, and anthropometric measurements, as well as glycemic, lipid, and liver profiles and liver stiffness measurements.Results The percentage of patients achieving the primary efficacy outcome did not differ significantly between the groups (32.7% in the silymarin group vs 26.0% in the placebo group; P = .467). A significantly higher proportion of patients in the silymarin group had reductions in fibrosis based on histology (reductions of 1 point or more; 22.4%) than did the placebo group (6.0%; P = .023), and based on liver stiffness measurements (decrease of 30% or more; 24.2%) than did the placebo group (2.3%; P = .002). The silymarin group also had significant reductions in mean aspartate aminotransferase to platelet ratio index (reduction of 0.14, P = .011 compared with baseline), fibrosis-4 score (reduction of 0.20, P = .041 compared with baseline), and NAFLD fibrosis score (reduction of 0.30, P < .001 compared with baseline); these changes were not observed in the placebo group (reduction of 0.07, P = .154; increase of 0.18, P = .389; and reduction of 0.05, P = .845, respectively). There was no significant difference between groups in number of adverse events; adverse events that occurred were not attributed to silymarin.Conclusions In a randomized trial of 99 patients, we found that silymarin (700 mg, given 3 times daily for 48 weeks) did not reduce NAS scores by 30% or more in a significantly larger proportion of patients with NASH than placebo. Silymarin may reduce liver fibrosis but this remains to be confirmed in a larger trial. It appears to be safe and well tolerated. ClinicalTrials.gov: NCT02006498.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2017.04.016

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 39 references

Research works printed but not linked: 1

  1. Loomba, 2016, GS-4997, an inhibitor of apoptosis signal-regulating kinase (ASK1), alone or in combination with simtuzumab for the treatment of nonalcoholic steatohepatitis (NASH): a randomized phase 2 trial, Hepatology, 64, 1119A

Cited by

Sorted by citations

Items 101–200 of 264

Related

See all

Metadata

Authors
Wah Kheong, C., Nik Mustapha, N. R., & Mahadeva, S.
Affiliations
University of Malaya (MY)
ORCID
Mahadeva, Sanjiv
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2017-12
Volume
15
Issue
12
Pages
1940-1949.e8
ISSN
1542-3565 (ISSN-L)
DOI
10.1016/j.cgh.2017.04.016
OpenAlex
W2607263910
Cited by
264
References
39
Citations by year
2026: 27 · 2025: 38 · 2024: 44 · 2023: 34 · 2022: 25 · 2021: 30 · 2020: 23 · 2019: 23 · 2018: 16 · 2017: 2
FWCI
14.48
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Clinical Gastroenterology and Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • The University of Malaya Research Repository (University of Malaya) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Silymarin and Mushroom Poisoning
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Complementary and alternative medicine › Nigella sativa pharmacological applications
Keywords
silymarin, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, Silybum marianum, flavonolignans, liver fibrosis, liver stiffness, NAFLD activity score, hepatocyte ballooning, steatosis, lobular inflammation, antifibrotic therapy, liver biopsy histology, Fibrosis-4 score, aspartate aminotransferase to platelet ratio index, hepatoprotection
MeSH terms
Adult, Aged, Antioxidants, Double-Blind Method, Female, Gastrointestinal Agents, Humans, Malaysia, Male, Middle Aged, Placebos, Silymarin, Treatment Outcome, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review